Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775918 | 0.94 | TRIM24 (0.40) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL1700931 | 0.94 | — | — | |
| SCHEMBL3241777 | 0.92 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL13563888 | 0.89 | — | — | |
| SCHEMBL2026824 | 0.84 | CYP2D6 (0.33) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL14441602 | 0.83 | TRIM24 (0.33) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL13084100 | 0.81 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL708873 | 0.81 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL19839354 | 0.80 | TRIM24 (0.33) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL29749761 | 0.80 | TRIM24 (0.33) | TRIM24TRIM33ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250179065-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| EP-4556469-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4551571-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-3494115-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents of The University of Michigan (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180354950-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-12-13 | — | — | US | disclosed |
| WO-2018027097-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018027097-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-1406891-B1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | BAYER HEALTHCARE AG (DE) | 2005-01-13 | — | — | US | disclosed |
| EP-1406891-A1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | Bayer HealthCare AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003053955-A1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | TRIM24 3300/4885TRIM33 3068/4885ALDH1A1 4625/4885 |
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | HTT, HMOX1, SNCA | TRIM24 1791/4885TRIM33 2091/4885ALDH1A1 1088/4885 |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | BCL2A1, BCL3, BCL2 | TRIM24 4417/4885TRIM33 4327/4885ALDH1A1 2910/4885 |
| US-20180354950-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL2A1, BCL3, BCL2 | TRIM24 4417/4885TRIM33 4327/4885ALDH1A1 2910/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | TRIM24 3958/4885TRIM33 4447/4885ALDH1A1 1304/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | TRIM24 1244/4885TRIM33 1406/4885ALDH1A1 1694/4885 |
| US-20250179065-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | TRIM24 954/4885TRIM33 1148/4885ALDH1A1 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.